No annual revenue total was found in Attovia Therapeutics, Inc.'s SEC filings.
Attovia Therapeutics, Inc. (ATTO) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances). As of Jun 30, 2026 it held $115.1 million in cash and investments and $4.3 million in total debt.
Revenue
—
Net income
—
Operating cash flow
—
Free cash flow
—
EPS
—
Dividend per share
None
Shares outstanding
—
Net cash
$110.81M
as of Jun 30, 2026
Operating margin
—
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- ATTO (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Carlos, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 2058707
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Sep 2, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Sep 2, 2026 | Sep 2, 2026 |
| 8-K |
Current report
Bylaw or fiscal year change
|
Aug 6, 2026 | Aug 6, 2026 |
All 56 Attovia Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.